256 related articles for article (PubMed ID: 31750620)
1. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal.
Lin YC; Chiu WN; Chang TS; Huang TJ; Chen MY
J Nurs Scholarsh; 2020 Mar; 52(2):128-135. PubMed ID: 31750620
[TBL] [Abstract][Full Text] [Related]
2. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach.
Li W; Chang TS; Chang SZ; Chen CH; Chen MY
BMC Infect Dis; 2020 Oct; 20(1):737. PubMed ID: 33028228
[TBL] [Abstract][Full Text] [Related]
3. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.
Shiha G; Metwally AM; Soliman R; Elbasiony M; Mikhail NNH; Easterbrook P
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):778-789. PubMed ID: 30030068
[TBL] [Abstract][Full Text] [Related]
4. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.
Tien HM; Cheng TC; Lien HC; Yang KF; Shy CG; Chen YL; Hsu NT; Lu SN; Wang JH
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328957
[TBL] [Abstract][Full Text] [Related]
5. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
6. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
7. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare.
Wang TJ; Chen MY; Lin YC; Chiu WN; Huang TJ; Weng HH
BMC Public Health; 2024 Feb; 24(1):532. PubMed ID: 38378519
[TBL] [Abstract][Full Text] [Related]
9. Early detection of unhealthy behaviors, the prevalence and receipt of antiviral treatment for disabled adult hepatitis B and C carriers.
Jane SW; Lin MS; Chiu WN; Lai LJ; Chen PH; Chen MY
BMC Public Health; 2016 Feb; 16():146. PubMed ID: 26873327
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
[TBL] [Abstract][Full Text] [Related]
11. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
12. Dual strategy involving hospital-based study and community-based screening to eliminate hepatitis C in remote areas.
Chen CH; Hsu NT; Chen IC; Chang TS; Cheng S; Cheng SY; Chen HM; Harn MR; Liu CK; Yang MT; Lu SL; Tseng CM; Lu SN
J Formos Med Assoc; 2024 May; 123(5):613-619. PubMed ID: 38195318
[TBL] [Abstract][Full Text] [Related]
13. Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan - A multi-center collaborative care model.
Lo CC; Lei WY; Huang YC; Hwang JJ; Lo CY; Lin CH; Cheng HS; Liao YT; Liang PC; Chiou MJ; Bair MJ; Dai CY; Yu ML
J Microbiol Immunol Infect; 2023 Aug; 56(4):680-687. PubMed ID: 36822945
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
15. The characteristics of residents with unawareness of hepatitis C virus infection in community.
Cheng PN; Chiu YC; Chiu HC; Chien SC
PLoS One; 2018; 13(2):e0193251. PubMed ID: 29470547
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy.
Piselli P; Serraino D; Fusco M; Girardi E; Pirozzi A; Toffolutti F; Cimaglia C; Taborelli M;
BMC Infect Dis; 2021 Jul; 21(1):667. PubMed ID: 34238231
[TBL] [Abstract][Full Text] [Related]
17. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.
Brouard C; Pillonel J; Boussac M; de Lédinghen V; Rachas A; Silvain C; Lydié N; Chevaliez S; Pioche C; Durand J; Lot F; Delarocque-Astagneau E
BMC Infect Dis; 2020 Oct; 20(1):759. PubMed ID: 33059617
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Liver Cancer Through the Early Detection of Risk-related Behavior Among Hepatitis B or C Carriers.
Fan JY; Huang TJ; Jane SW; Chen MY
Cancer Nurs; 2015; 38(3):169-76. PubMed ID: 24836958
[TBL] [Abstract][Full Text] [Related]
19. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data.
Silvestri C; Bartolacci S; Pepe P; Monnini M; Voller F; Cipriani F; Stasi C
World J Gastroenterol; 2016 Nov; 22(44):9829-9835. PubMed ID: 27956807
[TBL] [Abstract][Full Text] [Related]
20. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.
Yu ML; Yeh ML; Tsai PC; Huang CI; Huang JF; Huang CF; Hsieh MH; Liang PC; Lin YH; Hsieh MY; Lin WY; Hou NJ; Lin ZY; Chen SC; Dai CY; Chuang WL; Chang WY
Medicine (Baltimore); 2015 Apr; 94(13):e690. PubMed ID: 25837762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
